Pre-exposure prophylaxis (PrEP) is the use of drugs to prevent disease in people who have not yet been exposed to the disease-causing agent. The term typically refers to the use of antiviral drugs as a strategy for the prevention of HIV/AIDS.
PrEP is one of a number of HIV prevention strategies for people who are HIV negative but who also have higher-than-average risk of contracting HIV, including sexually active adults at increased risk of HIV (e.g. men who have sex with men), people who engage in injection drug use (see drug injection), and serodiscordant sexually active couples.
Currently, the only drug that any health organization recommends for HIV/AIDS PrEP is Truvada, which is the brand name of the Gilead Sciences drug combination of tenofovir/emtricitabine. Patients on PrEP take Truvada every day and must also agree to see their healthcare provider at least every three months for follow-up testing. When used as directed, PrEP has been shown to be highly effective at reducing the risk of contracting HIV. PrEP is intended for use along with other risk reduction strategies such as condoms because people taking PrEP are still at some risk of contracting HIV, especially those who do not take PrEP consistently, and because people on PrEP remain at risk for other types of sexually transmitted infection.
Video Pre-exposure prophylaxis
Clinical use
In the United States, federal guidelines recommend the use of PrEP for HIV-negative adults with the following characteristics:
- sexually active in the last 6 months and NOT in a sexually monogamous relationship with a recently tested HIV-negative partner, and who...
- is a man who has sex with men, and who...
- has had anal sex with another man in the past 6 months without a condom, or...
- has had a sexually transmitted infection in the past 6 months
- or is a sexually active adult (male or female with male or female partners), and who...
- is a man who has sex with both men and women, or...
- has sex with partners at increased risk of having HIV (e.g. injection drug users, men who have sex with men) without consistent condom use
- is a man who has sex with men, and who...
- or anyone who has injected illicit drugs in the past six months, shared recreational drug injection equipment with other drug users in the past six months, or who has been in treatment for injection drug use in the past six months
Other government health agencies from around the world have devised their own national guidelines for how to use PrEP to prevent HIV infection in those at high risk, including Botswana, Canada, Kenya, Lesotho, South Africa, Uganda, the United Kingdom, Zambia, and Zimbabwe.
Often, lab testing is required before starting PrEP, including a test for HIV. Once PrEP is initiated, patients are asked to see their provider at least every three to six months. During those visits, healthcare providers may want to repeat testing for HIV, test for other sexually transmitted infections, monitor kidney function, and/or test for pregnancy.
PrEP has been shown to be effective at reducing the risk of contracting HIV in individuals at increased risk. However, PrEP is not 100% effective at preventing HIV, even in people who take the medication as prescribed. There have been several reported cases of people who despite taking PrEP became infected with HIV. People taking PrEP are recommended to use other risk reducing strategies along with PrEP, like condoms. If someone on PrEP contracts HIV, they may experience the Signs and symptoms of HIV/AIDS.
Maps Pre-exposure prophylaxis
Side effects
Research has shown that PrEP is generally safe for most patients, although some side effects have been noted to occur. Some patients experience a "start-up syndrome" involving nausea, headache, and/or flatulance, which generally resolve within a few weeks of starting the PrEP medication. Research has shown that the use of Truvada as PrEP has been associated with mild declines in kidney function. These declines were mild, stabilized after several weeks of being on the drug, and reversed once the drug was discontinued.
Access and adoption
Approval for use
Truvada was previously only approved by the US Food and Drug Administration to treat HIV in those already infected. In 2012, the FDA approved the drug for use as PrEP, based on growing evidence that the drug was safe and effective at preventing HIV in populations at increased risk of infection.
In 2012, the World Health Organization issued guidelines for PrEP and made similar recommendations for its use among men and transgender women who have sex with men. The WHO noted that "international scientific consensus is emerging that antiretroviral drugs, including PrEP, significantly reduce the risk of sexual acquisition and transmission of HIV regardless of population or setting." In 2014, on the basis of further evidence, the WHO updated the recommendation for men who have sex with men to state that PrEP "is recommended as an additional HIV prevention choice within a comprehensive HIV prevention package." In November 2015 the WHO expanded this further, on the basis of further evidence, and stated that it had "broadened the recommendation to include all population groups at substantial risk of HIV infection" and emphasized that PrEP should be "an additional prevention choice in a comprehensive package of services."
As of 2017, numerous countries have now approved the use of PrEP for HIV/AIDS prevention, including the United States, France, Norway, Australia, Israel, Canada, Kenya, South Africa, Peru, Thailand, the European Union and Taiwan.
Availability and pricing
In the United States, PrEP is available only by prescription. Patients interested in learning more about PrEP can contact their healthcare providers. Emory University hosts a search engine to help US patients with or without insurance find healthcare providers who can prescribe PrEP.
PrEP drugs can also be expensive, with tremendous variation in cost across different countries. In the US, a prescription for PrEP can cost $8,000-$14,000/year. In the UK, a prescription for PrEP can cost about £4,200/year Some health organizations, including the U.K.'s NHS, have challenged the funding of PrEP out of concern for the cost. In Australia, for example, the country's Therapeutic Goods Administration approved the use of Truvada as PrEP, allowing Australian providers to legally prescribe the medication. However, as of 2017 Australia has opted not to include Truvada as PrEP on the country's Pharmaceutical Benefits Scheme, meaning that patients can be prescribed PrEP but may only be able to access the drug through clinical trials or by importing the drug from abroad.
Multiple programs exist to help make PrEP more accessible to those who might benefit from the drug. In 2015, the US CDC published guidelines to help American patients figure out how to pay for PrEP. Those with health insurance can find out from their health insurer whether PrEP and the associated costs (e.g. visits to the doctor, lab tests) would be covered. Those without health insurance or for whom health insurance has declined to pay for PrEP may be eligible for free PrEP from the drug's manufacturer, Gilead. A similar program exists to reduce or eliminate the cost of the copayment for PrEP among insured patients, also sponsored by Gilead. Others turn to online pharmacies to access cheaper generic versions of PrEP. For instance, a dramatic decline in new HIV infections in London, UK in 2016 has been attributed by some to access to PrEP through online pharmacies, although others have expressed concerns about the safety and reliability of accessing PrEP through such online pharmacies.
Politics and culture
Since the FDA approval of PrEP for the prevention of HIV, moves toward greater adoption of PrEP have been met with controversy, especially around the overall public health effect of widespread adoption, the cost of PrEP and associated disparities in availability and access. Many public health organizations and governments have embraced PrEP as a part of their overall strategy for reducing HIV. For example, in 2014 New York state governor Andrew Cuomo initiated a three-part plan to reduce HIV across New York that specifically emphasized access to PrEP. Similarly, the city of San Francisco launched a "Getting to Zero" campaign. The campaign aims to dramatically reduce the number of new HIV infections in the city and relies on expanding access to PrEP as a key strategy for achieving that goal. Public health officials report that since 2013 the number of new HIV infections in San Francisco has decreased almost 50% and that such improvements are likely related to the city's campaign to reduce new infections. Additionally, numerous public health campaigns have been launched to educate the public about PrEP. For instance, in New York City in 2016 Gay Men's Health Crisis launched an ad campaign in bus shelters across the city reminding riders that adherence to PrEP is important to ensuring the regimen is maximally effective.
Despite those efforts, PrEP remains controversial among some who worry that widespread PrEP adoption could cause public health issues by enabling risky sexual behaviors. For instance, AIDS Healthcare Foundation founder and director Michael Weinstein has been vocal in his opposition to PrEP adoption, suggesting that PrEP causes people to make riskier decisions about sex than they would otherwise make. Some researchers, however, believe that there is insufficient data to determine whether or not PrEP implementation has an effect on the rate of other sexually transmitted infections. Other critics point out that despite implementation of PrEP, significant disparities exist. For example, some point out that African Americans bear a disproportionate burden of HIV infections but may be less likely than whites to access PrEP. Still other critics of PrEP object to the high cost of the regimen. For example, the U.K.'s NHS initially refused to offer PrEP to patients citing concerns about cost and suggested that local officials ought to bear the responsibility of paying for the drug. However, following significant advocacy efforts, the NHS will start to offer PrEP to patients in the UK in 2017.
Research
Most PrEP studies utilize the drug tenofovir or a tenofovir/emtricitabine combination (Truvada) that is delivered orally. Initial studies of PrEP strategies in non-human primates showed a reduced risk of infection among animals that receive ARVs prior to exposure to a simian form of HIV. A 2007 study at UT-Southwestern (Dallas) and the University of Minnesota showed PrEP to be effective in "humanized" laboratory mice. In 2008, the iPrEx study demonstrated 42% reduction of HIV infection among men who have sex with men, and subsequent analysis of the data has suggested that 99% protection is achievable if the drugs are taken every day. Below is a table summarizing some of the major research studies that demonstrated PrEP with Truvada to be effective across different populations.
PrEP approaches with agents besides oral Truvada are being investigated. There has been some evidence that other regimens, like ones based on the antiretroviral agent Maraviroc, could potentially prevent HIV infection. Similarly, researchers are investigating whether drugs could be used in ways other than a daily oral pill to prevent HIV, including taking a long-acting PrEP injection, PrEP-releasing implants, or rectally administered PrEP. However, it is important to keep in mind that as of 2017 major public health organizations such as the US Centers for Disease Control and the World Health Organization recommend only daily oral Truvada for use as PrEP.
See also
- Post-exposure prophylaxis (PEP)
- National AIDS Trust v NHS Service Commissioning Board
References
Further reading
- Singh JA, Mills EJ (2005). "The Abandoned Trials of Pre-Exposure Prophylaxis for HIV: What Went Wrong?". PLoS Medicine. 2 (9): e234. doi:10.1371/journal.pmed.0020234. PMC 1176237 . PMID 16008507.
- Lange J (2005). "We Must Not Let Protestors Derail Trials of Pre-Exposure Prophylaxis for HIV". PLoS Medicine. 2 (9): e248. doi:10.1371/journal.pmed.0020248. PMC 1176241 . PMID 16008501.
External links
- PrEPWatch PrEP Watch homepage
- CDC CDC Pre-Exposure Prophylaxis (PrEP)
- Emory University PrEP Locator PrEP Locator
- CDC "Paying for PrEP" Guidelines Paying for PrEP
- Gilead Sciences PrEP Medication Assistance Program Medication Assistance Program
- Gilead Sciences Advancing Access Copayment Program Copayment Coupon Card
Source of article : Wikipedia
0 Comments